A sense of crisis in the biopharmaceutical industry is rising as the possibility of passing the 'drug price reduction/refund bill' in the plenary session of the National Assembly is increasing. The pharmaceutical industry is concerned that the amendment will infringe on the right to request a trial as stipulated in the Constitution, and furthermore, it will damage the domestic pharmaceutical and bio-industry as a whole. According to the pharmaceutical industry on the 16th, the revision of the National Health Insurance Act, the so-called Drug Price Reduction and Refund Act, proposed by Rep. Kim Won-i and Nam In-soon, respectively, will be decided at the National Assembly plenary session this month at the earliest. Acc